Nanoform Finland Oyj Valuation
Is NANOFH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NANOFH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NANOFH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NANOFH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NANOFH?
Other financial metrics that can be useful for relative valuation.
| What is NANOFH's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €126.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 25.6x |
| Enterprise Value/EBITDA | -4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NANOFH's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.4x | ||
HVO hVIVO | 2.2x | 6.5% | UK£135.7m |
TRJ Trajan Group Holdings | 1.1x | 5.9% | AU$182.7m |
4880 CellSource | 5.8x | 7.4% | JP¥28.1b |
6118 Austar Lifesciences | 0.4x | n/a | HK$891.9m |
NANOFH Nanoform Finland Oyj | 40.1x | 68.6% | €126.3m |
Price-To-Sales vs Peers: NANOFH is expensive based on its Price-To-Sales Ratio (40.1x) compared to the peer average (2.4x).
Price to Earnings Ratio vs Industry
How does NANOFH's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Sales vs Industry: NANOFH is expensive based on its Price-To-Sales Ratio (40.1x) compared to the European Life Sciences industry average (3.9x).
Price to Sales Ratio vs Fair Ratio
What is NANOFH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 40.1x |
| Fair PS Ratio | 23.7x |
Price-To-Sales vs Fair Ratio: NANOFH is expensive based on its Price-To-Sales Ratio (40.1x) compared to the estimated Fair Price-To-Sales Ratio (23.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.61 | €4.40 +173.3% | 2.3% | €4.50 | €4.30 | n/a | 2 |
| Dec ’24 | €1.67 | €4.40 +163.5% | 2.3% | €4.50 | €4.30 | n/a | 2 |
| Nov ’24 | €1.57 | €6.00 +282.2% | 8.3% | €6.50 | €5.50 | n/a | 2 |
| Oct ’24 | €1.78 | €6.00 +237.1% | 8.3% | €6.50 | €5.50 | n/a | 2 |
| Sep ’24 | €2.30 | €6.00 +160.9% | 8.3% | €6.50 | €5.50 | n/a | 2 |
| Aug ’24 | €1.79 | €7.00 +292.2% | 21.4% | €8.50 | €5.50 | n/a | 2 |
| Jul ’24 | €1.91 | €7.00 +266.5% | 21.4% | €8.50 | €5.50 | n/a | 2 |
| Jun ’24 | €2.16 | €7.00 +224.1% | 21.4% | €8.50 | €5.50 | n/a | 2 |
| May ’24 | €2.24 | €7.15 +219.2% | 23.1% | €8.80 | €5.50 | n/a | 2 |
| Apr ’24 | €1.59 | €7.15 +349.7% | 23.1% | €8.80 | €5.50 | n/a | 2 |
| Mar ’24 | €2.15 | €7.15 +232.6% | 23.1% | €8.80 | €5.50 | n/a | 2 |
| Feb ’24 | €2.99 | €8.88 +197.3% | 12.7% | €10.00 | €7.75 | n/a | 2 |
| Jan ’24 | €3.20 | €8.88 +177.3% | 12.7% | €10.00 | €7.75 | n/a | 2 |
| Dec ’23 | €3.06 | €8.88 +190.0% | 12.7% | €10.00 | €7.75 | €1.67 | 2 |
| Nov ’23 | €2.86 | €8.88 +210.9% | 12.7% | €10.00 | €7.75 | €1.57 | 2 |
| Oct ’23 | €3.15 | €8.88 +182.2% | 12.7% | €10.00 | €7.75 | €1.78 | 2 |
| Sep ’23 | €3.55 | €8.88 +150.4% | 12.7% | €10.00 | €7.75 | €2.30 | 2 |
| Aug ’23 | €3.60 | €8.88 +146.9% | 12.7% | €10.00 | €7.75 | €1.79 | 2 |
| Jul ’23 | €3.48 | €8.88 +155.0% | 12.7% | €10.00 | €7.75 | €1.91 | 2 |
| Jun ’23 | €4.01 | €8.88 +121.3% | 12.7% | €10.00 | €7.75 | €2.16 | 2 |
| May ’23 | €4.34 | €9.15 +111.1% | 9.3% | €10.00 | €8.30 | €2.24 | 2 |
| Apr ’23 | €4.25 | €9.15 +115.3% | 9.3% | €10.00 | €8.30 | €1.59 | 2 |
| Mar ’23 | €4.48 | €9.15 +104.2% | 9.3% | €10.00 | €8.30 | €2.15 | 2 |
| Feb ’23 | €5.62 | €9.15 +62.8% | 9.3% | €10.00 | €8.30 | €2.99 | 2 |
| Jan ’23 | €6.58 | €9.15 +39.1% | 9.3% | €10.00 | €8.30 | €3.20 | 2 |
| Dec ’22 | €6.75 | €9.15 +35.6% | 9.3% | €10.00 | €8.30 | €3.06 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.